New Distributor - MJS Biolynx

GlycoSeLect signs distribution agreement with MJS BioLynx Inc.

November 2021

GlycoSeLect is delighted to announce that it has signed an exclusive distribution agreement for its innovative RPL glycan specific technology in the Canadian market with MJS BioLynx Inc.

MJS BioLynx Inc. is a Canadian life sciences distribution company with over 40 years of distribution experience in Canada gained through its sister company Chromatographic Specialties Inc. MJS BioLynx specialises in providing high quality products for protein chemistry, immunology, molecular biology and microbiology as well as other life science disciplines. The team are committed to providing technical expertise and excellent customer service while maintaining a high inventory in order to ensure fast product delivery. With bilingual staff and Canada-wide Technical Sales Representatives,  MJS BioLynx work hard keeping customers informed of new products, new techniques and cutting-edge technology.

Welcoming the announcement, GlycoSeLect’s CEO Robert Dunne said MJS BioLynx Inc. will provide our Canadian customers with exceptional customer service, consistently providing them with our innovative glycan-specific RPL products from quick deliveries. It has been a pleasure working with Cherin, Steve and their team to establish our agreement. We look forward to supporting them in the future”

Find more information about GlycoSeLect’s innovative glycan specific RPL technology on our website. To learn more about MJS BioLynx Inc.’s high quality products, visit

About GlycoSelect Ltd

GlycoSeLect Ltd develops innovative technologies for the analysis, characterisation and purification of biopharmaceuticals. These next-generation products are highly specific for glycan structures improving product development and improving the cost-efficiency of their manufacturing. GlycoSeLect specialises in the development of proteins based on recombinant prokaryotic lectins RPLs. Our RPL products advance efficient detection, analysis and selective isolation of glycosylated pharmaceutical products. GlycoSeLect’s family of RPLs products are associated with market-leading properties, including high affinity for glycan targets, high sensitivity of detection, high stability and robustness in process development.

More Stories